Drug Discovery & Pharmaceuticals

RSS

Therapeutic in vivo synthetic chemistry used to make anticancer drugs

An international research group at the RIKEN Cluster for Pioneering Research (CPR) has successfully treated cancer in mice using metal catalysts that assemble anticancer drugs together inside the body.

10 Jan 2022

New molecule offers effective protection against coronavirus for at least eight hours

A molecule developed by researchers at the University of Helsinki can inactivate the coronavirus spike protein and offers effective short-term protection against the virus.

10 Jan 2022

NYBC discovers novel small-molecule pancoronavirus fusion inhibitors

New York Blood Center has published a study that reports the discovery of highly potent small molecules with the ability to inhibit COVID-19 in infected individuals.

9 Jan 2022

Slight pH adjustment may turn a metabolic inhibiting drug into promising COVID-19 treatment

Mechanical engineering and materials science professor David Needham has shown that a slight increase in solution pH might be all it takes to turn a metabolic inhibiting drug, traditionally used to treat gut parasites, into a promising prophylactic/preventative nasal spray and early treatment throat spray for COVID-19.

7 Jan 2022

New compound could combat multidrug-resistant pathogens in healthcare settings

For years, public-health experts have been sounding the alarm about the next phase in humanity's co-existence with bacteria - a dark future where emerging strains have rendered once-powerful antibiotics useless.

5 Jan 2022

Empire Discovery Institute collaborates with Novo Nordisk to launch new drug discovery initiative

Empire Discovery Institute entered into a five-year collaborative research partnership with global pharmaceutical company Novo Nordisk A/S to launch LeapRx, a new initiative where EDI and Novo Nordisk will co-invest, incubate and accelerate innovative drug discovery and development projects from its academic partners.

4 Jan 2022

Oxford researchers demonstrate the feasibility of increasing the speed and volume of vaccine production

The University of Oxford's vaccine manufacturing research team has today published a pre-print paper demonstrating the feasibility of a step change in the speed and volume of production of adenovirus-vectored vaccines against new virus variants or other future pandemics.

4 Jan 2022

Echinacea, a potent antiviral against SARS-CoV-2

Researchers present available evidence on the activity of Echinacea purpure against coronavirus infections.

3 Jan 2022

Exploring the importance of selenium in COVID-19 patients

In a new study, researchers reviewed research on the role that selenium could play in protecting individuals against coronavirus disease 2019.

29 Dec 2021

Introducing deuterium makes drugs to have a longer effect

Hydrogen (abbreviated "H") is the lightest of all elements. It usually consists only of a positively charged proton and a negatively charged electron and is also called protium in this form. But there are also two heavier hydrogen isotopes, deuterium and tritium.

24 Dec 2021

Researchers receive NIH grants to develop new treatments for neglected tropical diseases

Researchers at Washington University School of Medicine in St. Louis have received two grants from the National Institutes of Health totaling more than $5.5 million to develop new treatments for two types of devastating parasitic infections common in sub-Saharan Africa and Central and South America: river blindness and intestinal worm infections.

22 Dec 2021

Study suggests nitazoxanide fails to reduce the severity of SARS-CoV-2

A new study shows that the optimization of nitazoxanide formulations may allow the review of the potential use of the drug for the treatment of SARS-CoV-2 infection.

22 Dec 2021

Traditional medicinal plant alleviates malaria symptoms in mice

The active plant ingredient anemonin could provide a new approach in the treatment of malaria. It was identified by researchers from Ethiopia and Germany in a buttercup that is traditionally used in some African countries as a medicinal plant to treat malaria.

20 Dec 2021

Researchers identify two new AMD drug candidates using a stem-cell-derived model

Using a stem-cell-derived model, researchers have identified two drug candidates that may slow dry age-related macular degeneration (AMD), a leading cause of blindness for which no treatment exists.

15 Dec 2021

Salk study could help find better treatment options for colorectal cancer patients

Patients with colorectal cancer were among the first to receive targeted therapies. These drugs aim to block the cancer-causing proteins that trigger out-of-control cell growth while sparing healthy tissues.

14 Dec 2021

Recycling tubular endosomes are associated with effective delivery of mRNA-based therapeutics, study finds

A recent study recently demonstrates the endosomal transport of nanoparticle-based formulations for the effective delivery of mRNA-based therapeutics.

14 Dec 2021

Duke Human Vaccine Institute secures federal contract for advancing investigational vaccines

The National Institute of Allergy and Infectious Diseases awarded researchers at the Duke Human Vaccine Institute a contract that enables it to compete for projects advancing investigational vaccines to production for use in early clinical trials.

14 Dec 2021

Iota-carrageenan inhibits replication of SARS-CoV-2 VOCs

Scientists have recently reported the efficacy of carrageenan against both the SARS-CoV-2 original strain as well as the Alpha, Beta, Gamma, and Delta VOCs.

13 Dec 2021

The antiviral potential of 4′-fluorouridine as an oral treatment against RSV and SARS-CoV-2

New research reports 4’-Fluorouridine (4′-FlU) as an oral antiviral against RSV and SARS-CoV-2.

7 Dec 2021

Poolbeg and University College Dublin sign an Option Agreement to license melioidosis vaccine candidate

Poolbeg Pharma, 'Poolbeg' or the 'Company', a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has signed an Option Agreement to licence MelioVac, a vaccine for melioidosis, with University College Dublin and its inventor, Associate Professor Siobhán McClean, through NovaUCD, the university's knowledge transfer office.

7 Dec 2021

Drug Discovery & Pharmaceuticals

Therapeutic in vivo synthetic chemistry used to make anticancer drugs

New molecule offers effective protection against coronavirus for at least eight hours

NYBC discovers novel small-molecule pancoronavirus fusion inhibitors

Slight pH adjustment may turn a metabolic inhibiting drug into promising COVID-19 treatment

New compound could combat multidrug-resistant pathogens in healthcare settings

Empire Discovery Institute collaborates with Novo Nordisk to launch new drug discovery initiative

Oxford researchers demonstrate the feasibility of increasing the speed and volume of vaccine production

Echinacea, a potent antiviral against SARS-CoV-2

Exploring the importance of selenium in COVID-19 patients

Introducing deuterium makes drugs to have a longer effect

Researchers receive NIH grants to develop new treatments for neglected tropical diseases

Study suggests nitazoxanide fails to reduce the severity of SARS-CoV-2

Traditional medicinal plant alleviates malaria symptoms in mice

Researchers identify two new AMD drug candidates using a stem-cell-derived model

Salk study could help find better treatment options for colorectal cancer patients

Recycling tubular endosomes are associated with effective delivery of mRNA-based therapeutics, study finds

Duke Human Vaccine Institute secures federal contract for advancing investigational vaccines

Iota-carrageenan inhibits replication of SARS-CoV-2 VOCs

The antiviral potential of 4′-fluorouridine as an oral treatment against RSV and SARS-CoV-2

Poolbeg and University College Dublin sign an Option Agreement to license melioidosis vaccine candidate

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Leveraging the Radian ASAP in standard casework

Latest Life Science News